Evidence map›Paper›PMID 40593987›Full record

Trial reportScientific reports2025

Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.

James Goodman, Martin Schain, Giovanni Di Stefano, Victoria Lupson, Tracy Horn, Marion Hill, Roie Manavaki, Timothy D Fryer, Elaine Bumanlag-Amis, Navazh Jalaludeen and 9 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

James GoodmanDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK. james.goodman11@nhs.net.ORCID http://orcid.org/0000-0002-1659-7644
Martin SchainAntaros Medical AB, Mölndal, Sweden.
Giovanni Di StefanoClinical Pharmacology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Victoria LupsonDepartment of Clinical Neurosciences, Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.
Tracy HornDepartment of Clinical Neurosciences, Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.
Marion HillDepartment of Clinical Neurosciences, Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.
Roie ManavakiDepartment of Clinical Neurosciences, Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.
Timothy D FryerDepartment of Clinical Neurosciences, Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.
Elaine Bumanlag-AmisClinical Pharmacology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Navazh JalaludeenClinical Pharmacology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Lutz JermutusResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Edvin JohanssonAntaros Medical AB, Mölndal, Sweden.
Kerstin HeurlingAntaros Medical AB, Mölndal, Sweden.
Henrik HaraldssonAntaros Medical AB, Mölndal, Sweden.
Mark EvansWellcome Trust/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Joseph CheriyanDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.
Lars JohanssonAntaros Medical AB, Mölndal, Sweden.
Philip AmberyLate-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Ian B WilkinsonDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.

Funding

Department of Health NIHR203312NIHR Cambridge Biomedical Research Centre NIHR203312University of Cambridge-AstraZeneca Experimental Medicines Training Initiative RG98920, RG78426, RCAG/975 and RCZA/053
6 · The paper itself

Abstract

Type 2 diabetes (T2D) significantly increases the risk of heart failure, a major cause of hospitalisation and increased morbidity and mortality. Dual and multi-agonist synthetic peptides at the GLP-1 and glucagon receptor are in clinical development as potential new treatments for a range of chronic metabolic conditions including T2D. Here, we aimed to explore the effects of GLP-1 and glucagon dual receptor agonism on myocardial glucose uptake (MGU) and myocardial function in T2D. Eight adults with a mean age of 52 ± 12 years and body mass index 31 ± 4 kg/m

Indexed as

Diabetes Mellitus, Type 2ExenatideGlucagonGlucoseHypoglycemic AgentsMyocardiumAdultAgedBiomarkersDiastoleFemaleHumansMaleMiddle AgedBiomarkersExenatideGlucagonGlucoseHypoglycemic Agents18F-FDGCardiac MRICMRDual-agonismGLP-1GLP-1/glucagonGlucagonMyocardial glucose uptakePET MRI

Identifiers

PMID40593987
PMCPMC12217732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.